Monoclonal antibody glycosylation is a critical quality attribute that directly affects therapeutic efficacy, safety, and regulatory compliance. Glycans—particularly N-linked glycans at Asn 297 of the Fc region—govern key functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), serum half-life, and immunogenicity. Creative Biolabs offers comprehensive glycosylation engineering services through our proprietary GlycoOptimize™ platform, enabling precise and reproducible tailoring of glycosylation profiles across diverse production systems and scales.